Olverembatinib for FGFR1-rearranged Neoplasms

Inclusion Criteria: 1. Patients with newly diagnosed, progressed or relapsed myeloid/lymphoid neoplasms with FGFR1 rearrangement according to the WHO-2016 diagnostic criteria. Patients who have received allogeneic hematopoietic stem cell transplantation or ponatinib should be excluded. 2. ECOG score: MPNs patients, 0-3 points; AL patients, 0-2 points. 3. Expected survival period ≥12 weeks. 4. Willingness and ability to comply with study procedures and follow-up examination. Exclusion Criteria: 1. Patients who have received allogeneic hematopoietic stem cell or ponatinib. 2. Human immunodeficiency virus (HIV) infection, or chronic infection with hepatitis B virus (HBsAg positive) or hepatitis C virus (anti-HCV positive). 3. Patients who are pregnant, planning to become pregnant or breastfeeding. 4. Patients who may not be able to complete all study visits or procedures required by the study protocol, including follow-up visits, and/or fail to comply with all required study procedures. 5. Patients who suffer from any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of the safety of the research drug.